As Pfizer acquires CovX and Coley buy clears, small deals are expected to continue

Share this article:
Pfizer regroups businesses under global umbrellas
Pfizer regroups businesses under global umbrellas

Pfizer Tuesday agreed to buy biotherapeutics firm CovX. Financial terms were not disclosed.

La Jolla, CA,-based CovX will function as a division of Pfizer's new Biotherapeutic and Bioinnovation Center in California. CovX specializes in preclinical oncology and metabolic research. The deal is expected to close in the first quarter of 2008.

Meanwhile, Pfizer said it has cleared antitrust review in its acquisition of Massachusetts-based Coley Pharmaceutical, a biotech developing compounds to treat treat cancers, infectious diseases, asthma and allergy.

In a note to investors last week, Sanford Bernstein analyst Tim Anderson wrote that he expected Pfizer to continue to pursue smaller targets, an approach essentially in-line with peers and similar to Bristol-Myers Squibb's "string of pearls" approach.

“Our ‘best guess' is that for the next two years or so, Pfizer will continue to pour money into R&D and take the ‘string of pearls' approach to acquisitions, but after that, if the pipeline doesn't deliver the company may end up rethinking doing major deals within the sector,” Anderson wrote.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...